Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income from Continuing Operations (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Income from Continuing Operations for 2 consecutive years, with 77909000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 533.3% to 77909000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1067000.0 through Dec 2025, up 102.35% year-over-year, with the annual reading at 1067000.0 for FY2025, 102.35% up from the prior year.
  • Income from Continuing Operations hit 77909000.0 in Q4 2025 for Silence Therapeutics, up from 20958000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 77909000.0 in Q4 2025 to a low of 35544000.0 in Q3 2024.